Blood Cancer News and Research

RSS

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

Engineered yeast cells accelerate testing of cancer immunotherapies

Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

4 Feb 2026

New study exposes a targetable vulnerability in acute myeloid leukemia

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response.

19 Jan 2026

Single-cell technique maps pre-malignant gene mutations in solid tissues

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

16 Jan 2026

Multiple myeloma rates increasing twice as high in men than in women

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men than in women

12 Jan 2026

Single-cell analysis illuminates myeloma immune landscape

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable.

9 Jan 2026

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure.

9 Jan 2026

Epigenetic plasticity in germinal center B cells may help explain lymphoma origins

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more flexible, or plastic, stem-cell-like state in the lymph nodes, according to a new preclinical study from Weill Cornell Medicine investigators.

30 Dec 2025

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

22 Dec 2025

New AI model brings precision medicine to multiple myeloma care

C. Ola Landgren, M.D., Ph.D., received HealthTree Foundation's prestigious 2025 Innovation Award for his work in developing CORAL, a new research tool that leverages AI to predict individual outcomes and guide treatment decisions in patients with multiple myeloma.

19 Dec 2025

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive similar care despite differences in disease characteristics and outcomes.

12 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

New consortium aims to fast-track breakthroughs against follicular lymphoma

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not require immediate treatment.

1 Dec 2025

Blood Cancer News and Research

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Engineered yeast cells accelerate testing of cancer immunotherapies

New study exposes a targetable vulnerability in acute myeloid leukemia

Single-cell technique maps pre-malignant gene mutations in solid tissues

Multiple myeloma rates increasing twice as high in men than in women

Single-cell analysis illuminates myeloma immune landscape

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

Epigenetic plasticity in germinal center B cells may help explain lymphoma origins

Precision immunotherapy for TRBC2-positive T-cell malignancies

New AI model brings precision medicine to multiple myeloma care

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Patients receiving T-cell redirecting therapies can safely be monitored at home

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Powerful prognostic marker could enable early identification of high-risk cancer patients

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Timing of genetic mutation dictates childhood leukemia aggressiveness

New consortium aims to fast-track breakthroughs against follicular lymphoma

Everything you should know about lymphoma eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News